Ruksolitynib w leczeniu nowotworów mieloproliferacyjnych Ph(-)

Publication date: Available online 26 July 2015 Source:Acta Haematologica Polonica Author(s): Tomasz Wróbel Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis and post-polycythaemia vera myelofibrosis and post-essential thrombocytaemia myelofibrosis. The article is a summary of current clinical data with ruxolitinib therapy both in myelofibrosis and in other Ph-negative myeloproliferative neoplasms.
Source: Acta Haematologica Polonica - Category: Hematology Source Type: research